Price increases are the biggest driver of rising emergency room visit costs across the U.S., according to research led by the Center for Health and Biosciences' Vivian Ho and Sasathorn Tapaneeyakul.
The authors examine a proposal for new human embryo and embryoid guidelines, writing that before conducting any research beyond day 14, scientists must develop clear, thoughtful and culturally sensitive guidelines that include limitations and oversight procedures to ensure that science responds to societal needs and values.
Kirstin R.W. Matthews, Ana S. Iltis, Sam LoweDecember 21, 2021
This journal article explores why the public and stakeholders should help develop guidelines and policies governing scientific practices for controversial biomedical research issues, such as genetically editing human embryos.
Kirstin R.W. Matthews, Ana S. Iltis, Sarah HooverSeptember 22, 2021
It now seems technically feasible to culture human embryos beyond the “fourteen‐day limit,” which has the potential to increase scientific understanding of human development and perhaps improve infertility treatments. Robust stakeholder engagement preceded adoption of the fourteen‐day limit and should arguably be part of efforts to reassess it, write the authors.
Kirstin R.W. Matthews, Ana S. Iltis, Daniel S. Wagner, Nuria Gallego Marquez, Jason Scott Robert, Inmaculada de Melo-Martín, Marieke Bigg, Sarah Franklin, Soren Holm, Ingrid Metzler, Matteo A. Molè, Jochen Taupitz, Giuseppe Testa, Jeremy SugarmanFebruary 26, 2021
Expanded “payment bundles” for the treatment of end stage kidney disease did not in general increase the risk of closure by dialysis facilities, the authors conclude.
Sayna Norouzi, Bo Zhao, Ahmed Awan, Wolfgang Winkelmayer, Vivian Ho, Kevin EricksonFebruary 5, 2020
The results of this study suggest that Medicare Data on Provider Practice and Specialty, which costs less to obtain than from a for-profit data source, can be used to reliably track the cost and quality effects of vertical integration between hospitals and physicians.
A growing number of stem cell clinics treat a variety of illnesses and injuries, yet few have conducted the necessary clinical research to ensure safety and efficacy.
The authors highlight the importance of collaboration between scientists, regulators, patients and patient advocates in developing effective policies and practices for unproven stem cell-based intervention clinics.
The authors explore the different scientific values and priorities that should be considered in setting the policy agenda for effectively combating neglected tropical diseases (NTDs) and argue that researchers and physicians should participate in this process.